265 million yuan to enrich the blood and deep in Guangdong and Guangxi or for the electric business platform

Reporter found that the increase of 16 subsidiaries are the main pharmaceutical distribution companies, including "Guangdong Logistics" and "Shenzhen Logistics" two pharmaceutical logistics related industries. Financial weekly Trainee reporter Xu Jia/Shanghai reported 1.265 billion yuan in the internal capital increase, involving its 16 holding subsidiaries. Whether from the amount or the range, the common medicines (000028, shares bar) (000028. SZ) 's move had to cause a flurry of the two-tier market. As one of the listed subsidiaries of the group, the Chinese medicine industry has been quietly transforming from the pharmaceutical manufacturing industries to the pharmaceutical business sector. The increase of 16 subsidiaries only for its holding part of the enterprise, and its deep deep in Guangdong and Guangxi region of the pharmaceutical distribution business, it can be from its intermittent acquisition action to see the clue. In order to promote the marketing network to Guangdong and Guangxi region, the second-tier cities sank, the company completed the end of last year, Shantou boss of the acquisition. Multi-channel through the drug field of medicine in the same 16 additional subsidiaries, 15 are located in Guangdong, 1 are located in Guangxi. Financial Weekly (http://www.lczb.net) reporter observation found that these enterprises are mainly in the field of pharmaceutical distribution companies, including "Guangdong Logistics" and "Shenzhen Logistics" two pharmaceutical logistics and other related industrial chain coincide. However, the 16 subsidiaries have high asset-liability ratios, with all companies exceeding 80%. Its China-controlled zhaoqing, state-controlled Meizhou, the state-controlled Huizhou, three enterprises in the assets and liabilities ratio of nearly 95%. These enterprises do bear the same in the Guangdong region of the important distribution business, but debt management may be the inevitable link in the drug circulation industry, but the weakening of capital is indeed the weakness of decided. The 1.265 billion-dollar supplement is no doubt a relief of the pressure on the funds, but also shows the consensus in the field of the determination to add chips. As the group has the largest listed enterprises, the market value of 18.7 billion yuan of the same, in the middle of February this year stood 58.01 yuan in the history of the highest, after a few waves of small shocks, the recent smooth integration of the state, the stock price has been hovering around 50 yuan. The first half of 2014 reported that pharmaceutical business accounted for the company's main revenue of 91.81%, become the core business. In 2013, the first of all, the company began to test the mode of electronic commerce, which is the business of business-to-business control in Guangzhou. On this basis, the subsidiary also hopes to launch a business, but so far, the operator's licence has not yet been successfully applied. In fact, the reason why TCM is anxious to open the door to the drug circulation, in view of the Bureau of the Electronic Commerce platform sales of prescription drugs regulatory policy adjustment. Originally, because the electric commercial platform mostly sells the OTC medicine, the prescription medicine becomes the taboo place. This is why drug dealers are always drifting away in the edge of the industry is an important reason. But according to people familiar with the bureau, the Internet drug sales will push the new deal. Part of the prescription drug industry allowing online trading will be a big bright spot. It can be imagined that there will beHow to fight. For itself there are a number of chain entities pharmacies sales model of the same, the layout of the electricity business, the company will be more powerful than the pharmaceutical companies grasp the drug circulation policy vane. The same information from the people inside the bureau shows that "entrusting third party distribution" is another important signal of this policy adjustment. According to the relevant provisions of the State, pharmacies and hospital terminal logistics distribution to achieve a certain qualification, and because of the specificity of drugs, the feasibility of the construction of the logistics is still very low. On the one hand, will raise the cost of products, on the other hand, the construction of logistics needs to meet the GSP certification, and even to reach the cold chain distribution requirements, these will bring risks to the operation. Therefore, entrusting the third party logistics has become the choice of many pharmaceutical dealers. Although logistics and warehousing services accounted for only 0.11% of the same main income, but it is the development of pharmaceutical electrical business important support. It is reported that the Pharmaceutical Logistics Co., Ltd. Guangzhou branch was established in 1993, is the "logistics" of the Southern Logistics Center, set drugs, medical equipment, chemical reagents, professional third-party logistics providers. The DTC model is a new type of pharmacy trusteeship which is sought by the same. The so-called DTC, that is, high value drug direct delivery, is a higher value of the drug-focused more than the point of distribution, directly facing end consumers. The sale of drugs for the sale of large diseases, including cancer drugs, blood drugs, psychotropic drugs, customer cluster, collection and tracking and service costs are low, medication time is long. For companies with a pharmaceutical business, such as the same, the DTC pharmacy will promote the sales of pharmaceuticals in addition to the company's commercial margin. Since 2013, it has entered into the field of pharmacy trusteeship and opened 6 DTC pharmacies, which are to be fully promoted in Guangdong and Guangxi. Participate in state-owned enterprise reform as the parent company of the group was named into the first batch of state-owned enterprise reform pilot Enterprises, the Chinese medicine industry has been a consistent combination of ownership reform has attracted much attention. According to Shi Yi-yi, a spokesman for the group, the next step is to actively promote the Central Enterprise Board of Directors to exercise three functions (Executive selection rights, performance appraisal rights, compensation rights) of the pilot work, further improve the corporate governance structure, through the establishment and improvement of the group of senior management Personnel selection system, performance appraisal system and remuneration system, We should evaluate the performance of senior executives scientifically, enhance the independence, authority and effectiveness of the Board of Directors of the group, and strengthen the leading role of the Board in the group management decision. The market once believed that the mixed change of the Chinese medicine group will start from the unlisted company, but in view of the group's industrial layout, the pharmaceutical circulation industry is more suitable for the pilot. Because the commercial circulation industry relatively easy to introduce the social capital, but the pharmaceutical industry can only take the acquisition, the participation mode to Xi Shi state-holding status. Based on this point of view, the same will bear the responsibility of SOE reform. And analysts from the Dongguan securities that the reform and equity incentives will be an important catalyst for the same, especially in the parent company of the group on employee shareholding and mixed ownership of the scheme has been reported to the State Council SASAC, the future of the consistent reform of the Chineseis an inevitable trend, including a package of incentive packages. The figures also mention the possibility of a pay-for-market, which he predicts will be expected to expand from 20% to 40%. Industrial and commercial wing full strength Although the project does not involve drug manufacturing subsidiaries, this does not mean that the Chinese medicine is consistent with the field of Miss and laissez-faire. Dice-bao Antibiotics is an important product of the same, and these years the impact of policy restrictions on the field of profitability caused a small impact, but from the beginning of this year began to gradually warmer trend. According to the Half-year report data show, the pharmaceutical Division sales revenue 907 million, an increase of 3.8%. The Department of Pharmaceutical sales warmed up to achieve the ownership of the listed company's shareholders net profit of 136 million, an increase of 14.5%. The first half of the industry gross profit margin of 40.57%, increase 0.36pp. Oriental Securities analysts believe that the same in the cephalosporin powder needle gradually out of the limit to resist negative effects of recovery growth, non-cephalosporins and non-penicillin products slow-release diclofenac sodium growth of about 10%. Federal cough dew sales are estimated to be flat for the same period last year; export sales are about 9 million dollars. In addition, the company also continued to accelerate the pace of new product research and development, the first half of 2014 a total of 12 new products, the declaration of 2 production documents, the declaration of 8 clinical documents. In the research project a total of 127, CDE acceptance number 58, among them, the specialized medication project accounted for more than 60%, the first imitation drug project accounted for more than 40%, the research and development product line transformation effect is remarkable, these all have laid the good foundation for the following Ping Shan Base production product reserve.